Effect of metoclopramide on nausea and emesis in dogs premedicated with morphine and dexmedetomidine

Vet Anaesth Analg. 2018 Mar;45(2):190-194. doi: 10.1016/j.vaa.2017.09.042. Epub 2017 Nov 7.

Abstract

Objective: To evaluate whether subcutaneous (SC) metoclopramide (0.2 mg kg-1) administered 30 minutes prior to (T30) or simultaneously with (T0) intramuscular (IM) morphine (0.2 mg kg-1) and dexmedetomidine (0.003 mg kg-1) reduces the incidence of nausea and emesis in healthy dogs.

Study design: Prospective, randomized and blinded study.

Animals: A total of 45 dogs scheduled for elective procedures.

Methods: Dogs were assigned randomly to three groups to be administered SC metoclopramide (0.2 mg kg-1) 30 minutes before (group M30) or simultaneously (group M0) to IM morphine (0.2 mg kg-1) and dexmedetomidine (0.003 mg kg-1). Dogs in the control group (group C) were administered SC saline at T30 and T0. Dogs were observed for 30 minutes after premedication to evaluate signs of nausea (continuous lip-licking and sialorrhoea) and emesis. Signs of pain or discomfort caused by SC injections were also recorded.

Results: There were no statistical differences amongst groups for age, body weight and sex. More dogs developed continuous lip-licking in group C (12/15, 80.0%) compared to dogs in group M30 (1/15, 6.7%) and dogs in group M0 (5/15, 33.3%; p = 0.0001 and p = 0.01, respectively). More dogs developed sialorrhoea in group M0 (8/15, 53.3%) and in group C (10/15, 66.7%) compared to dogs in group M30 (2/15, 13.3%; p = 0.03 and p = 0.004, respectively). More dogs vomited in group M0 (4/15, 26.7%) and in group C (9/15, 60.0%) compared to dogs in group M30 (0/15, 0.0%; p = 0.05 and p = 0.0003, respectively). None of the dogs demonstrated signs of pain or discomfort during SC metoclopramide injection.

Conclusions and clinical relevance: Subcutaneous metoclopramide at 0.2 mg kg-1 may reduce IM morphine and dexmedetomidine-induced nausea and emesis if administered 30 minutes in advance. It is effective in reducing lip-licking even when administered concurrently with IM morphine-dexmedetomidine.

Keywords: dexmedetomidine; dogs; emesis; metoclopramide; morphine.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / adverse effects*
  • Analgesics, Opioid / antagonists & inhibitors
  • Animals
  • Antiemetics / therapeutic use*
  • Dexmedetomidine / administration & dosage
  • Dogs*
  • Dopamine Antagonists / therapeutic use
  • Female
  • Male
  • Metoclopramide / therapeutic use*
  • Morphine / administration & dosage
  • Morphine / adverse effects*
  • Morphine / antagonists & inhibitors
  • Nausea / chemically induced
  • Nausea / veterinary*
  • Premedication / veterinary
  • Single-Blind Method
  • Vomiting / chemically induced
  • Vomiting / veterinary*

Substances

  • Analgesics, Opioid
  • Antiemetics
  • Dopamine Antagonists
  • Dexmedetomidine
  • Morphine
  • Metoclopramide